Perrigo | PRGO - Des Atouts





Des Atouts Changement Date
AbbVie USD 136.46B 2.5B 2026-03
Abbott USD 110.43B 23.72B 2026-03
Bayer EUR 107.94B 3.4B 2026-03
Bristol-Myers Squibb USD 86.48B 3.56B 2026-03
Coherus Biosciences USD 258.34M 258.18M 2025-12
Corcept Therapeutics USD 814.88M 21.77M 2026-03
Dr.Reddys Laboratories INR 581.23B 18.34B 2026-03
Eli Lilly USD 116.58B 4.1B 2026-03
J&J USD 200.89B 1.68B 2026-03
Merck USD 128.68B 8.18B 2026-03
Nestle CHF 127.15B 2.97B 2025-12
Pacira USD 1.21B 56.38M 2026-03
Perrigo USD 7.98B 551.9M 2026-03
Pfizer USD 207.62B 542M 2026-03
Phibro Animal Health USD 1.45B 39.56M 2026-03
Prestige Brands USD 3.49B 430K 2026-03
Reckitt Benckiser GBP 25.3B 1.11B 2024-12
Sanofi EUR 128.02B 1.22B 2026-03
Supernus Pharmaceuticals USD 1.5B 48.08M 2026-03
Teva Pharmaceutical Industries USD 40.04B 708M 2026-03
Xeris Pharmaceuticals USD 392.01M 8.49M 2026-03
Zoetis USD 15.15B 313M 2026-03